Literature DB >> 9829780

Dystrophin binding to nonmuscle actin.

B A Renley1, I N Rybakova, K J Amann, J M Ervasti.   

Abstract

We purified actin from bovine brain by DNase I affinity chromatography in order to compare the binding of dystrophin to muscle actin with its binding to nonmuscle actin. While both beta- and gamma-nonmuscle actins are expressed in brain, Western blot analysis with isoform-specific antibodies indicated that our purified brain actin was exclusively the gamma-isoform. The recombinant amino-terminal, actin-binding domain of dystrophin bound to muscle and brain actin in a saturable manner (approximately 1 mol/mol actin) with similar Kd values of 13.7+/-3.5 and 10.6+/-3.7 microM, respectively. We further demonstrate that intact dystrophin in the dystrophin-glycoprotein complex bound with equal avidity to muscle and brain F-actin. These data argue that a preferential binding of dystrophin to nonmuscle actin is not the basis for its targeting to the muscle cell plasmalemma but do support the hypothesis that dystrophin is capable of interacting with filamentous actin in nonmuscle tissues.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829780     DOI: 10.1002/(SICI)1097-0169(1998)41:3<264::AID-CM7>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  16 in total

1.  Binding of dystrophin's tandem calponin homology domain to F-actin is modulated by actin's structure.

Authors:  A Orlova; I N Rybakova; E Prochniewicz; D D Thomas; J M Ervasti; E H Egelman
Journal:  Biophys J       Date:  2001-04       Impact factor: 4.033

Review 2.  Tropomodulins: pointed-end capping proteins that regulate actin filament architecture in diverse cell types.

Authors:  Sawako Yamashiro; David S Gokhin; Sumiko Kimura; Roberta B Nowak; Velia M Fowler
Journal:  Cytoskeleton (Hoboken)       Date:  2012-05-04

3.  Quadriceps myopathy caused by skeletal muscle-specific ablation of β(cyto)-actin.

Authors:  Kurt W Prins; Jarrod A Call; Dawn A Lowe; James M Ervasti
Journal:  J Cell Sci       Date:  2011-02-15       Impact factor: 5.285

Review 4.  Transverse tubule remodelling: a cellular pathology driven by both sides of the plasmalemma?

Authors:  David J Crossman; Isuru D Jayasinghe; Christian Soeller
Journal:  Biophys Rev       Date:  2017-07-10

5.  Specific interaction of the actin-binding domain of dystrophin with intermediate filaments containing keratin 19.

Authors:  Michele R Stone; Andrea O'Neill; Dawn Catino; Robert J Bloch
Journal:  Mol Biol Cell       Date:  2005-07-06       Impact factor: 4.138

6.  Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle.

Authors:  Inna N Rybakova; Jitandrakumar R Patel; Kay E Davies; Peter D Yurchenco; James M Ervasti
Journal:  Mol Biol Cell       Date:  2002-05       Impact factor: 4.138

7.  Cytoplasmic gamma-actin contributes to a compensatory remodeling response in dystrophin-deficient muscle.

Authors:  Laurin M Hanft; Inna N Rybakova; Jitandrakumar R Patel; Jill A Rafael-Fortney; James M Ervasti
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-24       Impact factor: 11.205

8.  Hypertrophic stimulation increases beta-actin dynamics in adult feline cardiomyocytes.

Authors:  Sundaravadivel Balasubramanian; Santhosh K Mani; Harinath Kasiganesan; Catalin C Baicu; Dhandapani Kuppuswamy
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

9.  Context-dependent functional substitution of alpha-skeletal actin by gamma-cytoplasmic actin.

Authors:  Michele A Jaeger; Kevin J Sonnemann; Daniel P Fitzsimons; Kurt W Prins; James M Ervasti
Journal:  FASEB J       Date:  2009-03-11       Impact factor: 5.191

10.  Dynamics of Dystrophin's Actin-Binding Domain.

Authors:  Michael E Fealey; Benjamin Horn; Christian Coffman; Robert Miller; Ava Y Lin; Andrew R Thompson; Justine Schramel; Erin Groth; Anne Hinderliter; Alessandro Cembran; David D Thomas
Journal:  Biophys J       Date:  2018-06-20       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.